Table 1 The patient and treatment characteristics (n = 62)
Characteristics | PI group | PI + EBRT group | ||||
|---|---|---|---|---|---|---|
Free seed | IBCL seed | p value | Free seed | IBCL seed | p value | |
Patients | 14 | 10 | Â | 25 | 13 | Â |
Age (years) | 70.5 ± 5.9 | 72.5 ± 6.4 | 0.859 | 73 ± 4.1 | 735 ± 4.5 | 0.093 |
Intra-operative prostate volume (cm3) | 18.9 ± 4.7 | 18.5 ± 10.6 | 0.595 | 18.9 ± 7.7 | 16.7 ± 9.7 | 0.734 |
Post-operative prostate volume (cm3) | 16.4 ± 5.6 | 17.8 ± 9.7 | 0.507 | 16.4 ± 6.9 | 16.5 ± 10.0 | 0.326 |
Initial PSA (ng/mL) | 7.1 ± 3.1 | 8.9 ± 4.6 | 0.344 | 8.8 ± 16.4 | 13.4 ± 27.9 | 0.424 |
Clinical stage | Â | Â | NA | Â | Â | 0.077 |
 T1c-T2a | 12 | 9 |  | 11 | 5 |  |
 T2b | 2 | 1 |  | 3 | 6 |  |
 T2c-T3a | 0 | 0 |  | 11 | 2 |  |
Gleason sum | Â | Â | NA | Â | Â | NA |
 ≤6 | 1 | 0 |  | 0 | 0 |  |
 7 | 13 | 10 |  | 2 | 1 |  |
 ≥8 | 0 | 0 |  | 23 | 12 |  |
Risk group | Â | Â | NA | Â | Â | NA |
 Low | 1 | 0 |  | 0 | 0 |  |
 Intermediate | 13 | 10 |  | 0 | 0 |  |
 High | 0 | 0 |  | 25 | 13 |  |
Implanted seed number | 65.5 ± 8.8 | 63.5 ± 11.2 | 0.780 | 51 ± 10.3 | 47 ± 9.6 | 0.318 |
Total activity (MBq) | 748 ± 141 | 715 ± 250 | 0.652 | 561 ± 134 | 517 ± 143 | 0.465 |